Clinical Trials Logo

Low Rectal Cancer clinical trials

View clinical trials related to Low Rectal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05972655 Recruiting - Low Rectal Cancer Clinical Trials

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

mRCAT
Start date: August 2, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tislelizumab) for patients with MSS middle and low rectal cancer. A total of 32 patients will be enrolled in this trial. The primary endpoint is the rate of pathological complete response (pCR). The organ preservation rate, tumor regression grade, long-term prognosis, and adverse effects will also be analyzed.

NCT ID: NCT02488577 Enrolling by invitation - Low Rectal Cancer Clinical Trials

Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer

TAMIS
Start date: June 2015
Phase: N/A
Study type: Interventional

Cases with stage T2 N0 low rectal cancer will undergo either Transanal minimally invasive total mesorectal excision or transanal minimally invasive locoregional resection.

NCT ID: NCT02468362 Enrolling by invitation - Low Rectal Cancer Clinical Trials

Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.

ISR-TME
Start date: April 2014
Phase: Phase 2
Study type: Interventional

Through a double blinded study, patients with low rectal cancer will be randomized into two equal groups to compare between the 5 year disease free survival as a primary outcome measure.